Pharma Stocks Rally: Nifty Pharma Rises 2% as Dr Reddy's, Sun Pharma and Cipla Lead Rally

Pharmaceutical stocks emerged as the top-performing segment of the market on Tuesday, outperforming major benchmark indices. The Nifty Pharma index climbed nearly 2% in early trade, while the Nifty 50 and Sensex remained largely flat.

At around 9:39 AM, the Nifty Pharma index was up 1.88%, making it the best-performing sectoral index on the NSE.

Dr Reddy's, Sun Pharma and Cipla Among Top Gainers

Among the Nifty 50 stocks, pharma companies dominated the gainers' list.

• Dr Reddy’s Laboratories rose 2.64% to ₹1,324.80.
• Sun Pharmaceutical Industries gained 1.68% to ₹1,894.20.
• Cipla advanced 1.22% to ₹1,433. 

These 3 stocks emerged as the top performers on the benchmark index during the session.

Midcap Pharma Stocks Rally 

The positive momentum extended to midcap pharmaceutical companies as well. On the BSE Midcap index, several healthcare stocks featured among the top gainers.

Emcure Pharmaceuticals jumped over 5%, while Laurus Labs, Gland Pharma, Aurobindo Pharma, Alkem Laboratories, and Ipca Laboratories also recorded strong gains, reflecting broad-based buying across the sector.

What Triggered the Rally in Pharma Stocks?

The rally followed reports that the US Food and Drug Administration (US FDA) has approached Indian pharmaceutical manufacturers to help address a shortage of ifosfamide injection, a generic chemotherapy drug used in the treatment of cancers such as bladder, lung, and testicular cancer.

According to reports, the US regulator reached out through the Indian Drug Manufacturers' Association (IDMA) to identify companies capable of supplying the medicine quickly. Indian drugmakers, known for their strong presence in the global generics market, are well-positioned to support the supply requirement.

Why Indian Pharma Companies Could Benefit

India is one of the world's largest producers of generic medicines and supplies a significant share of pharmaceutical products to global markets, including the United States. Any increase in export opportunities arising from supply shortages could potentially benefit Indian drug manufacturers and strengthen their market position.

Read more: Best Gold Stocks in June 2026 Based on 5‑Year CAGR: Sky Gold and Diamonds, Laxmi Goldorna House and More.

Conclusion

Pharma stocks outperformed the broader market on June 23, driven by reports of potential export opportunities linked to a shortage of chemotherapy drugs in the US. With leading companies such as Dr Reddy's, Sun Pharma, and Cipla attracting investor interest, the sector remains in focus as demand for Indian generic medicines continues to grow globally.

For daily market updates and regular stock market news in Hindi, stay tuned to Angel One's share market news in Hindi. 

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation or investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions.

Investments in the securities market are subject to market risks. Read all related documents carefully before investing.